|
|
Home > Healthcare > Biotechnology > Genetics & Genomics
Novel Targets in Drug Discovery
|
|
D&MD’s Novel Targets in Drug Discovery report provides an overview of the concept of drug targets, and discusses their place in modern drug discovery. The report looks at the role of technologies such as genomics, proteomics and bioinformatics in target identification, as well as describing the downstream processes such as target validation, lead discovery, lead optimization and clinical development. It also discusses the various types of drug targets using specific examples where appropriate and provides an overview of novel targets currently moving through advanced clinical trials.
In recent years, the process of drug discovery has changed immeasurably. It has gone from a process that was largely disease-focused to one that is target-led. This change has been driven by a number of factors—among them technological advances and economic pressures.
Under the old paradigm, drug discovery began with the identification of a human disease and the development of an animal model of it. Chemical compounds that ameliorated the animal disease were then used as the starting point for the development of a new therapeutic substance. The present approach focuses very much on the identification of potential drug targets, which are typically individual genes or gene products. If the gene underlying a particular disease can be identified, the reasoning goes, then the discovery of chemical compounds or biological agents that modulate the targets, and therefore hopefully treat the disease, can be automated. This approach should be vastly more efficient than dealing with animal models.
However, not everyone agrees that this genetic reductionist approach is valid. While it appears superficially attractive, a number of objections, both theoretical and practical, have been raised. Nevertheless, it has been widely embraced by the pharmaceutical industry. Part of this acceptance is based on the increase pace of life sciences basic research over the past two decades.
This report provides an overview of the concept of drug targets, and discusses their place in modern drug discovery. It looks at the role of technologies such as genomics, proteomics and bioinformatics in target identification, as well as describing the downstream processes such as target validation, lead discovery, lead optimization and clinical development. It also discusses the various types of drug targets using specific examples where appropriate and provides an overview of novel targets currently moving through advanced clinical trials.
|
Similar Products
• Biotechnology Sector
Published Nov 2009 by First Research, Inc.
• Dealmaking and Industry Outlook: Neurological Disease
Published Nov 2009 by Decision Resources
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• The Human Genome Sequencing Center at Baylor College of Medicine Relies on Quantum's StorNext Software for Data Management
Published Oct 2009 by IDC
• Genetic Engineering
Published Oct 2009 by Global Industry Analysts
• Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2009-2018
Published Oct 2009 by Venture Planning Group
• Preventive Healthcare Technologies, Products and Markets
Published Oct 2009 by BCC Research
• Transfection Life Science Dashboard™ Series 2
Published Oct 2009 by Percepta Associates, Inc.
• Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook
Published Oct 2009 by Business Insights
|
|
|
|
0 items
